Seeking Alpha

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
syracuse.com

FDA approves updated COVID shots, but millions won’t be allowed to get one

WASHINGTON — U.S. regulators approved updated COVID-19 shots Wednesday but limited their use for many Americans — and removed one of the two vaccines available for young children. The new shots ...
Insider Monkey

Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. Novavax, Inc.
Drug Store News

FDA approves Novavax's Nuvaxovid 2025-2026 formula COVID-19 vaccine

The Food and Drug Administration has approved Novavax's Nuvaxovid 2025-2026 formula for the prevention of COVID-19 in adults 65 years and older or individuals 12 years through 64 years of age with ...